logo-loader
/**/ p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .o{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.o{}p.ap{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-left:12.0pt;text-align:justify;text-indent: -12.0pt}span.an{font-size:20.0pt;font-family:"Calibri","sans-serif"; letter-spacing:-.05pt}span.am{font-size:20.0pt; font-family:"Calibri","sans-serif"}p.aq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-indent:-12.0pt}span.ak{font-size:14.0pt; font-family:"Calibri","sans-serif"}p.ar{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:21.15pt;margin-bottom: 0cm;margin-left:12.0pt;margin-bottom:.0001pt;text-indent:-12.0pt}span.ai{font-size:14.0pt;font-family:"Calibri","sans-serif";letter-spacing:-.05pt}p.ad{text-align:justify} span.ag{font-size:11.0pt;font-family: "Calibri","sans-serif"}span.af{font-size: 11.0pt;font-family:"Calibri","sans-serif"}span.ae{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.as{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}table.at{width:439.45pt;margin-left:-9.9pt;border-collapse:collapse}tr.w{height:33.3pt}td.z{width:281.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:33.3pt}p.au{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}span.ab{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.av{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} td.x{width:136.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:33.3pt}p.aw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify; text-indent: -1.25pt}td.v{width:281.45pt;padding:0cm 5.4pt 0cm 5.4pt}td.u{width:136.4pt;padding:0cm 5.4pt 0cm 5.4pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.t{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.ax{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-indent: -1.25pt}p.ay{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-indent:-1.25pt}a.r{font-weight: bold} /**/
RNS Number : 6718U
SkinBioTherapeutics PLC
26 November 2019
 

SkinBioTherapeutics plc

 

Notice of AGM

Manchester, UK - 26 November 2019 - SkinBioTherapeutics plc (AIM: SBTX) a life sciences company focused on skin health, announces its Annual General Meeting will be held on 19 December 2019 at 11am at Centurion House, 129 Deansgate, Manchester, M3 3WR.

A copy of the notice of AGM will be available on the Company's website today.

 

For more information, please contact:

 

SkinBioTherapeutics plc

Stuart Ashman, CEO

Doug Quinn, CFO

 

Tel: +44 (0) 161 468 2760

Cairn Financial Advisers LLP (Nominated Adviser)

Tony Rawlinson / Sandy Jamieson

 

Tel: +44 (0) 20 7213 0880

SP Angel Corporate Finance (Joint Broker)

Vadim Alexandre / Abigail Wayne

 

Tel: +44 (0) 20 3470 0470

 

Turner Pope Investments (Joint Broker)

Andy Thacker / Zoe Alexander

 

 

Tel: +44 (0) 20 3657 0050

 

Instinctif Partners

Melanie Toyne-Sewell / Phil Marriage / Nathan Billis

 

Tel: +44 (0) 20 7457 2020

   [email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOACKADQFBDKFDB

Quick facts: SkinBioTherapeutics PLC

Price: 13.578

Market: AIM
Market Cap: £17.39 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA). Ashman says it's a significant first...

on 20/11/19